Lymphoblastic Leukemia, Acute, Childhood Active Not Recruiting Phase 2 Trials for Tisagenlecleucel (DB13881)

DBCOND0044925 (Lymphoblastic Leukemia, Acute, Childhood)Active Not Recruiting2 IdentifierTitlePurposeDrugs
NCT02435849Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed < 6 Months Post All-HSCT.Treatment